Guggenheim Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Neutral 66.2%

Neg 0% Neu 66.2% Pos 0%

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $50.